#EULAR2024 Cutaneous #lupus is variable & can be difficult to treat. Promising post-hoc data frm Phase 2 RCT showing
Tweet Content
#EULAR2024 Cutaneous #lupus is variable & can be difficult to treat. Promising post-hoc data frm Phase 2 RCT showing Deucravacitinib (Tyk2-i) led to improvement & sustained CLASI-50 response in all subtypes (ACLE, SCLE, Chonic and Discoid) @RheumNow #EULARBEST https://t.co/ArAzdLYiYY
Links
Show on Archive Page
On
Display in Search Results
On
PDQ
Off